Last €0.32 EUR
Change Today +0.002 / 0.62%
Volume 0.0
3AQ On Other Exchanges
Symbol
Exchange
London
Berlin
As of 2:08 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

e-therapeutics plc (3AQ) Snapshot

Open
€0.32
Previous Close
€0.32
Day High
€0.32
Day Low
€0.32
52 Week High
05/17/13 - €0.40
52 Week Low
03/19/14 - €0.22
Market Cap
85.5M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
263.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for E-THERAPEUTICS PLC (3AQ)

Related News

No related news articles were found.

e-therapeutics plc (3AQ) Related Businessweek News

No Related Businessweek News Found

e-therapeutics plc (3AQ) Details

e-Therapeutics plc engages in the discovery and development of drugs through its proprietary platform in network pharmacology in the United Kingdom. The company focuses on the discovery of cancer and degenerative diseases of the nervous system. Its drug candidates include ETS2101, which is in Phase I clinical trial for the treatment of brain cancer in the United States, and for the treatment of solid tumors in the United Kingdom; ETS6103, a Phase IIb trial product for depressive disorders; and ETX1153c, a preclinical stage drug for the treatment of C. difficile infection. The company was founded in 2001 and is based in Long Hanborough, the United Kingdom.

18 Employees
Last Reported Date: 07/1/13
Founded in 2001

e-therapeutics plc (3AQ) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: 415.0K GBP
Development Director and Executive Director
Total Annual Compensation: 215.0K GBP
Compensation as of Fiscal Year 2013.

e-therapeutics plc (3AQ) Key Developments

Steve Medlicott Joins e-Therapeutics plc. as Finance Director

e-Therapeutics plc announced that Steve Medlicott has joined the company as Finance Director. Medlicott joins e-Therapeutics' management team having previously advised the company in its £40 million fundraising in 2013. He is a Chartered Accountant, trained with PwC, and has previously taken the role of Director responsible for Finance at Waste2Tricity. Mr. Medlicott held key business development and sell-side analyst roles with Peel Hunt, N+1 Singer, Altium Capital and Williams de Broe. e-Therapeutics confirmed that Steven (Steve) Medlicott is currently a director of Blueprint Advisors Limited, Frenchay Interests Limited and Waste2Tricity Limited, and that there are no other disclosures to be made.

e-Therapeutics plc announces Executive Changes

e-Therapeutics plc announced that Dr. Daniel Elger has resigned as Chief Financial Officer and a Director with immediate effect. In the interim, e-Therapeutics' finances will be managed by Mr. Paul Stockdale, who has been the company's Financial Controller since January 2012. Paul is a Chartered Accountant, and was a Senior Manager at Deloitte before roles in finance and operations management in the charitable and automotive sectors. He took First Class Honours in Natural Sciences at Cambridge. An announcement concerning succession will be made at the appropriate time.

e-Therapeutics plc Reports Positive Interim Results from UK Phase Ia Trial of ETS2101 (dexanabinol) in a Variety of Solid Tumours

e-Therapeutics plc announced interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours. Following the completion of six dose escalation steps up to 22mg/kg, ETS2101 was found to be well tolerated at all doses by all patients with no serious adverse events attributed to the drug reported. In an earlier cohort, a single incident of dose-limiting fatigue was noted, but has not been repeated in any other patient to date. In addition, analysis of data from the trial indicates that tumour development might be being retarded by the activity of ETS2101 in patients who joined the trial with progressive disease with a wide variety of tumour types. The UK Clinical Investigators therefore intend to continue to enrol further patients at higher dose levels, and to continue to escalate until a maximum tolerated dose has been established. The observation that progression of the tumour might be affected by higher doses of ETS2101 is clearly one that the UK Principal Clinical Investigator is keen to explore further.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3AQ:GR €0.32 EUR +0.002

3AQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3AQ.
View Industry Companies
 

Industry Analysis

3AQ

Industry Average

Valuation 3AQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact E-THERAPEUTICS PLC, please visit www.etherapeutics.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.